Listen: J&J’s vaccine pause, how to talk about remote risks, & why we don’t have new drugs for Covid-19
How do you describe a one-in-a-million risk? What’s heparin-induced thrombocytopenia? And why’s it so hard to find drugs for Covid-19?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, Science Magazine reporter Kai Kupferschmidt joins us to discuss the U.S. decision to press pause on the Johnson & Johnson vaccine and what researchers have learned about rare cases of dangerous clotting. Then, biotech analyst Josh Schimmer joins us to talk about why the drug industry has had such a hard time coming up with treatments for Covid-19 and offer some tips that might help in the next pandemic.
